Metropolis Healthcare Limited has released its Investor & Analyst Meet 2026 presentation. The document outlines the company’s strategic vision, including strengthening its core, expanding adjacencies, and compounding shareholder value. Key highlights include its robust national network, financial performance over three years, growth engines, and emphasis on technology, talent, and governance. The presentation details FY26 revenue of ₹1,646 Cr and a projected revenue growth of 14-15% for FY27.
Metropolis Healthcare Investor & Analyst Meet 2026
Metropolis Healthcare Limited presented its strategic outlook and performance at the Investor & Analyst Meet 2026. The company’s overarching strategy revolves around strengthening its core business, expanding into new adjacencies, and compounding shareholder value. The presentation underscores a commitment to leveraging technology and scientific differentiation to achieve sustained profitable growth.
Company at a Glance
Metropolis boasts a strong national network and a legacy spanning over 45 years, with 209 laboratories and 5,000+ collection centres. The company serves over 750 towns in India and five international markets. For FY26, Metropolis reported a revenue of ₹1,646 Cr across its B2C and B2B segments. Approximately ~30,000 prescribing specialists and leading hospital chains are clients. B2C constitutes 57% of revenue through owned and franchisee networks.
Market Context and Growth Drivers
The Indian diagnostics market is projected to grow to $28.5 Bn by 2034 at an 11% CAGR, with a notable shift towards organized players. Metropolis is focusing on three key shifts: the move to organized care, healthcare expansion beyond metros, and advancing treatment pathways. The company’s competitive advantage, or ‘moat,’ is built on clinician trust and quality.
Scientific Capability and Performance
Metropolis offers over 2,200 specialty tests, including oncology, neurology, nephrology, and allergy. The company achieved 99% / 99.99% EQAS score and report accuracy. Its scientific capabilities are further bolstered by 35 NABL labs and 2 CAP-accredited genomics labs, along with a Medical Advisory Board of over 60 experts.
Financially, Metropolis demonstrated strong performance over three years (FY24-26). Revenue grew from ₹1,190 Cr in FY24 to ₹1,646 Cr in FY26, with a CAGR of 23.6%. EBITDA and Profit After Tax also saw significant increases during this period. Margin reached 24.4%, with volume-led growth driven by a 12% increase in patient volume and 13% in test volume without price increases.
Strategic Outlook and Growth Engines
The company’s strategy for the future involves five growth engines: Network expansion (scaling to 1,000 stores), TruHealth (integrating wellness, radiology, and consults), Specialty (growing advanced testing), Technology (digital platforms and automation), and Inorganic acquisitions. The focus is on improving revenue per patient and cost efficiency.
Financial Guidance and Outlook
The guidance for FY27 projects a full-year revenue growth of 14-15%, assuming no price increase. Q1 FY27 revenue grew 17% YoY to ₹450 Cr, exceeding trajectory. EBITDA margin improvement is guided at +100-150 bps. Key levers include strong B2C growth, specialty test expansion, and increased Tier III revenue.
Source: BSE
